论文信息 - Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups - 字舞流文

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

A. Jakubowiak | Sharmila Patel | J. Laubach | P. Richardson | R. Orlowski | P. Voorhees | J. Kaufman | S. Holstein | D. Sborov | A. Chari | K. Shain | A. Cowan | C. Costello | T. Wildes | N. Shah | R. Silbermann | H. Pei | B. Reeves | C. Rodriguez | N. Nathwani | N. Bumma | L. Anderson | T. Lin | L. Costa | A. Cortoos | Saad Z. Usmani